Gastrointestinal safety across the albiglutide development programme.

Item

http://www.wikidata.org/entity/Q53162146

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Gastrointestinal safety across the albiglutide development programme.

@en

Gastrointestinal safety across the albiglutide development programme.

@nl

type

Item

label

Gastrointestinal safety across the albiglutide development programme.

@en

Gastrointestinal safety across the albiglutide development programme.

@nl

prefLabel

Gastrointestinal safety across the albiglutide development programme.

@en

Gastrointestinal safety across the albiglutide development programme.

@nl

P1476

Gastrointestinal safety across the albiglutide development programme.

@en

P2093

J M Mallory

http://www.w3.org/2001/XMLSchema#string

L A Leiter

http://www.w3.org/2001/XMLSchema#string

R R Reinhardt

http://www.w3.org/2001/XMLSchema#string

T H Wilson

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes.

Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis.

Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.

Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing

The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review.

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.

Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not contr

Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5.

Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study.

HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.

P304

930-935

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/DOM.12679

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27097971

http://www.w3.org/2001/XMLSchema#string